Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia

Blood Adv. 2023 Aug 8;7(15):3838-3841. doi: 10.1182/bloodadvances.2023009818.

Authors

Amber Afzal¹, Mark A Fiala², Meagan A Jacoby², Matthew J Walter²

Affiliations

¹ Division of Hematology, Department of Medicine, Washington University in St. Louis, St. Louis, MO.
² Division of Oncology, Department of Medicine Washington University in St. Louis, St. Louis, MO.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Leukemia*
Myelodysplastic Syndromes* / drug therapy

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors